secwatch.observer — SEC 8-K summary
======================================

Issuer:     Chemours Co (CC)
CIK:        0001627223
Form:       8-K
Filed at:   2024-02-29T23:59:59+00:00
Accession:  0001193125-24-051940
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Chemours places CEO and CFO on leave; internal review finds potential material weaknesses; delays 10-K
--------------------------------------------------------------------------------

- CEO Mark Newman, CFO Jonathan Lock, Controller Camela Wisel placed on administrative leave pending internal review.
- Interim CEO Denise Dignam appointed; Interim CFO Matt Abbott appointed.
- Internal review includes ethics hotline, working capital practices, non-GAAP metrics; evaluating potential material weaknesses in internal control.
- Company delays Q4 2023 earnings release and 10-K filing; will file NT 12b-25.
- Preliminary 2023 net sales ~$6.0B (down 12% YoY); net loss $225-235M vs $578M net income in 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1627223/000119312524051940/0001193125-24-051940-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1627223/000119312524051940/d784750d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-051940

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer